Ransmayr, Lucia
Fuchs, Alexandra
Ransmayr-Tepser, Sibylle
Kommenda, Romana
Kögl, Mariella
Schwingenschuh, Petra
Fellner, Franz
Guger, Michael
Eggers, Christian
Darkow, Robert
Mangesius, Stephanie
Ransmayr, Gerhard http://orcid.org/0000-0001-9982-1420
Funding for this research was provided by:
Oesterreichische Nationalbank (13240)
Article History
Received: 30 March 2022
Accepted: 12 June 2022
First Online: 12 July 2022
Declarations
:
: Lucia Ransmayr, Alexandra Fuchs, Sibylle Ransmayr-Tepser, Romana Kommenda, Franz Fellner, Christian Eggers, Robert Darkow and Stephanie Mangesius have nothing to declare. Mariella W. Kögl received honoraria as a speaker and consulting honoraria from AbbVie GmbH. Petra Schwingenschuh received consulting honoraria from AbbVie GmbH and Bial. Michael Guger received support and honoraria for research, consultation, lectures and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire and TEVA ratiopharm. Gerhard Ransmayr received research support from the Jubilee Funds of the Austrian National Bank and the Austrian Research Promotion Funds, honoraria as speaker and for consultations from AbbVie GmbH, Alpine Market Research, Biogen, Grünenthal, MedAhead, Novartis Pharma GmbH, Ratiopharm, Roche Austria GmbH, Sanofi Aventis GmbH, Stada Arzneimittel-Gesellschaft, UCB Pharma GmbH. There are no competing financial or non-financial interests of the authors.
: The study was conducted according to the Declaration of Helsinki and approved by the local ethics review board (Ethikkommission des Landes Oberösterreich; FTLA Study, Protocol Number 254).
: Written informed consent was obtained from the patients and their caring family members.
: The study was approved by the Ethikkommission des Landes Oberösterreich (application number 254) and conducted according to the 1975 Helsinki declaration. Participants gave their informed written consent.